DK1007566T3 - Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf - Google Patents

Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf

Info

Publication number
DK1007566T3
DK1007566T3 DK98912339T DK98912339T DK1007566T3 DK 1007566 T3 DK1007566 T3 DK 1007566T3 DK 98912339 T DK98912339 T DK 98912339T DK 98912339 T DK98912339 T DK 98912339T DK 1007566 T3 DK1007566 T3 DK 1007566T3
Authority
DK
Denmark
Prior art keywords
therapeutic
well
molecules
present
preventing
Prior art date
Application number
DK98912339T
Other languages
English (en)
Inventor
Francois Rougeon
Catherine Rougeot
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK1007566T3 publication Critical patent/DK1007566T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/854—Glands

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK98912339T 1997-02-20 1998-02-19 Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf DK1007566T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/801,405 US6589750B2 (en) 1997-02-20 1997-02-20 Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives

Publications (1)

Publication Number Publication Date
DK1007566T3 true DK1007566T3 (da) 2007-01-02

Family

ID=25181003

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98912339T DK1007566T3 (da) 1997-02-20 1998-02-19 Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf

Country Status (10)

Country Link
US (4) US6589750B2 (da)
EP (2) EP1702929A3 (da)
AT (1) ATE337339T1 (da)
AU (1) AU6721998A (da)
CA (1) CA2281912A1 (da)
DE (1) DE69835680T2 (da)
DK (1) DK1007566T3 (da)
ES (1) ES2271991T3 (da)
PT (1) PT1007566E (da)
WO (1) WO1998037100A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
ATE414529T1 (de) * 1999-06-23 2008-12-15 Pasteur Institut Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
DE60018085T2 (de) * 2000-12-22 2005-07-07 Institut Pasteur Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden
BR122018074353B8 (pt) 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2390075T3 (es) * 2004-03-19 2012-11-06 Institut Pasteur Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos
DE102004026744A1 (de) * 2004-05-28 2005-12-29 Philipps-Universität Marburg Erfindung betreffend cDNA-Herstellung aus Zellen nach Laser-Mikrodissektion
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5788788B2 (ja) 2008-04-07 2015-10-07 アンスティテュ パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ エンケファリンを分解するエクトペプチダーゼを強力に阻害するオピオルフィンペプチド誘導体
FR2931362B1 (fr) 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
CN109212006A (zh) * 2018-08-24 2019-01-15 北京艾普希隆生物科技有限公司 一种单细胞琼脂糖凝胶电泳试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107708B1 (en) 1982-05-06 1987-10-28 Massachusetts Institute Of Technology Production of enterovirus neutralizing antibodies from vp1
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
GB8327966D0 (en) 1983-10-19 1983-11-23 Nyegaard & Co As Chemical compounds
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US5219548A (en) * 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
EP0705433A4 (en) * 1993-06-23 2001-09-26 Univ California Compositions and methods for anti-addictive narcotic analgesis acivity screening and treatments
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
ATE414529T1 (de) * 1999-06-23 2008-12-15 Pasteur Institut Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
DE60018085T2 (de) * 2000-12-22 2005-07-07 Institut Pasteur Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden

Also Published As

Publication number Publication date
US20030195155A1 (en) 2003-10-16
US20040047805A1 (en) 2004-03-11
US7429448B2 (en) 2008-09-30
US20020198361A1 (en) 2002-12-26
ES2271991T3 (es) 2007-04-16
EP1702929A2 (en) 2006-09-20
WO1998037100A2 (en) 1998-08-27
AU6721998A (en) 1998-09-09
EP1007566B1 (en) 2006-08-23
DE69835680T2 (de) 2007-08-23
US6818405B2 (en) 2004-11-16
US20020019008A1 (en) 2002-02-14
US6589750B2 (en) 2003-07-08
ATE337339T1 (de) 2006-09-15
EP1702929A3 (en) 2007-05-23
EP1007566A2 (en) 2000-06-14
PT1007566E (pt) 2007-01-31
WO1998037100A3 (en) 1999-01-07
CA2281912A1 (en) 1998-08-27
DE69835680D1 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
NO953781L (no) Terapeutisk anvendelse av keratinocyttvekstfaktor
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
IL141021A (en) Use of copolymer-like polypeptide-1 to prepare a drug to treat autoimmune diseases
EA200300845A1 (ru) Модифицированные антитела и способы применения
DE60043197D1 (da)
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
BR0212897A (pt) Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
ATE433959T1 (de) Analoge von kokain
SI2157192T1 (sl) Sestavki za diagnozo in terapijo bolezni, povezanih z aberantno ekspresijo Futrinov (R-Spondinov)
AU9363398A (en) Hepatitis c receptor protein cd81
DE69727691D1 (de) Verwendung von keratinocyten-wachstumsfaktor-2
WO2001017558A3 (en) Novel uses of mammalian ccr6 receptors and related reagents
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
WO2002007676A3 (en) Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr)
DE59909356D1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
BG101846A (bg) Варианти на човешка дезоксирибонуклеаза i
WO2000026362A3 (de) Proteine der stomatinfamilie und ihre verwendung als zielproteine für die schmerztherapie
FI972121A0 (fi) Sammansaettningar foer reciprok oekning av immunosupperssanters och interferoners farmaceutiska aktiviteter